Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Cantuzumab mertansine
Другие языки:

Cantuzumab mertansine

Подписчиков: 0, рейтинг: 0
Cantuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1). It was developed by ImmunoGen.

Mechanism

After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.

Clinical trials

Three phase I clinical studies had reported results by 2003. By 2005, clinical development had been suspended.

See also


Новое сообщение